Brokerages Set Inspire Medical Systems, Inc. (NYSE:INSP) Target Price at $66.19

Inspire Medical Systems, Inc. (NYSE:INSP) has been assigned a consensus rating of “Hold” from the nineteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $66.1875.

A number of equities research analysts have weighed in on INSP shares. Mizuho upped their price target on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Tuesday, August 4th. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a report on Friday, May 22nd. Evercore set a $54.00 target price on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Truist Financial restated a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a report on Tuesday, August 4th.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.20% of the stock is currently owned by insiders.

Institutional Trading of Inspire Medical Systems

A number of hedge funds have recently modified their holdings of INSP. Royal Bank of Canada grew its position in Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after purchasing an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems during the 1st quarter valued at $524,000. Goldman Sachs Group Inc. boosted its stake in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after buying an additional 18,857 shares during the period. Marshall Wace LLP grew its holdings in shares of Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after acquiring an additional 577 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in shares of Inspire Medical Systems during the 2nd quarter valued at $931,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Up 2.5%

Shares of INSP stock opened at $68.14 on Friday. The company has a market cap of $1.97 billion, a P/E ratio of 14.75, a PEG ratio of 5.05 and a beta of 0.70. The business has a 50 day moving average of $56.60 and a two-hundred day moving average of $52.51. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The company’s quarterly revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Analysts expect that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.